August 19, 2026 10:24 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Supreme Court rejects ‘less painful’ death penalty plea, but leaves door open for future change | ‘Vulgarity and disgust’: DMK attacks Vijay over Trisha salute at I-Day event | ‘Take Gyanesh Kumar to the US’: Congress mocks Trump over praise for India’s voter ID system | Big relief for Imran Khan: Pakistan Supreme Court orders hospital transfer amid health fears | Trump praises India’s voter ID system, pushes SAVE America Act | Trump's shock threat to bomb Oman: US President warns ally over Iran deal and Hormuz crisis | Rishabh Pant scripts history! Indian wicketkeeper-batter joins elite 100-sixes club in Test cricket | BJP reshuffles top organisation seven months after Nitin Nabin's elevation | West Bengal STF arrests suspected aide of ISI 'agent' Rana Rauf in Kolkata | ‘Very hopeful’: Indian envoy Dinesh Trivedi breaks silence on PM Tarique Rahman’s proposed India visit

Philippines healthcare providers administer vaccine approved for prevention of Dengue

| | Feb 23, 2016, at 05:00 am
Kolkata/Lyon, Feb 22 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday that vaccinations with Dengvaxia have commenced in the Philippines following official receipt of the first shipment of the vaccine earlier this month.
Dengvaxia, a tetravalent dengue vaccine, was approved in the Philippines on 22 December 2015 for the prevention of disease caused by all four Dengue types in individuals from 9-45 years of age living in endemic areas. 
 
The vaccine is administered in three doses given over a one-year period. Asia bears 70% of dengue fever burden globally with an estimated 67 million people being sickened by the disease annually. 
 
In the Philippines alone, over 110,000 people on average get Dengue every year. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to Dengue.
 
“This is truly a great moment in the history of vaccinology,” states Guillaume Leroy, Vice-President of Dengue Vaccine, Sanofi Pasteur. “Dengvaxia’s availability for administration by healthcare providers in the Philippines, to be followed closely by the initiation of a public sector immunization program in the country is a landmark event for global Dengue prevention and a great achievement for the people of the Philippines.”
 
Medical Societies in the Philippines held a media event in Manila earlier this month to welcome receipt of the first shipment of Dengvaxia to the country.
 
In attendance, Dr. Rose Capeding, chief of the Research Institute for Tropical Medicine’s department of microbiology, noted that the Philippines participated in all three phases of the clinical development of the vaccine and that healthcare providers there were delighted to be able to begin vaccinating against dengue, which continues to pose a major public health threat to the nation.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.